Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213032 | 0.92 | TP53 (0.49) | LMNATP53MEN1KMT2AMAPT | |
| SCHEMBL5211647 | 0.90 | TP53 (0.40) | LMNAALDH1A1TP53MEN1KMT2A | |
| SCHEMBL5211199 | 0.89 | MAPT (0.53) | LMNAALDH1A1TP53MEN1KMT2A | |
| SCHEMBL5209074 | 0.88 | TP53 (0.45) | LMNAALDH1A1TP53MEN1RAB9A | |
| SCHEMBL5214089 | 0.87 | KMT2A (0.49) | LMNAALDH1A1TP53MEN1KMT2A | |
| SCHEMBL5210908 | 0.85 | PKM (0.42) | LMNAL3MBTL1TP53MEN1KMT2A | |
| SCHEMBL5209795 | 0.85 | ASAH1 (0.38) | LMNAALDH1A1L3MBTL1TP53TSHR | |
| SCHEMBL5210310 | 0.85 | P2RX7 (0.39) | LMNAALDH1A1L3MBTL1TP53MAPT | |
| SCHEMBL5209979 | 0.85 | CNR1 (0.39) | LMNAALDH1A1L3MBTL1TP53KMT2A | |
| SCHEMBL5207508 | 0.84 | ALDH1A1 (0.46) | LMNAALDH1A1L3MBTL1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | LMNA 4253/4885ALDH1A1 1651/4885L3MBTL1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.